Table I.
Cases of trastuzumab monotherapy-induced ILD.
| Age/gender | Setting | Previous CRT | Duration after Tmab initiation | Pattern on CT | Treatment | Recovery | Refs. |
|---|---|---|---|---|---|---|---|
| 49/F | Adjuvant | AC, RT, D | 3 months | Focal (OP) | Steroid, antibiotics | Yes | (10) |
| 72/F | Palliative | None | 3 months | Diffuse (DAD) | Steroid | No | (11) |
| 65/F | Adjuvant | EC, PTX | 5 weeks | Diffuse (DAD) | Steroid, antibiotics | Yes (slow recovery) | (12) |
| 56/F | Palliative | DT | 19 weeks | Diffuse (CT: np) | Steroid | Yes | (13) |
| 68/F | Adjuvant | EC, RT | 3 months | Diffuse (DAD) | Steroid, antibiotics | Yes | Case 1 |
| 77/F | Adjuvant | EC | On first a administration | Diffuse (HP) | Steroid | Yes | Case 2 |
| 62/F | Adjuvant | DCT | 3 months | Focal (OP) | Steroid | Yes (slow recovery) | Case 3 |
ILD, interstitial lung disease; F, female; M, male; CRT, chemoradiotherapy; Tmab, trastuzumab; RT, radiotherapy; CT, computed tomography; np, not performed; D, docetaxel; AC, doxorubicin and cyclophosphamide; EC, epirubicin and cyclophosphamide; PTX, paclitaxel; DT, docetaxel and trastuzumab; DCT, docetaxel, cyclophosphamide and trastuzumab; OP, organizing pneumonia; DAD, diffuse alveolar damage; HP, hypersensitivity pneumonia.